Benazepril ( DrugBank: Benazepril )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 49 | Systemic lupus erythematosus | 1 |
| 57 | Idiopathic dilated cardiomyopathy | 1 |
| 218 | Alport syndrome | 3 |
| 224 | Purpura nephritis | 1 |
49. Systemic lupus erythematosus
Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04486118 (ClinicalTrials.gov) | October 1, 2021 | 28/10/2019 | Centrally Acting ACE Inhibition in SLE | A Novel Phase 2 Double-blind, Randomized, Controlled Clinical Trial to Evaluate the Efficacy of Centrally Acting, Non-toxic ACE Inhibition in Cognitive Impairment Associated With SLE | Systemic Lupus Erythematosus | Drug: Lisinopril Pills;Drug: Benazepril Pill | Northwell Health | Lupus Research Alliance | Recruiting | 18 Years | 55 Years | All | 36 | Phase 2 | United States |
57. Idiopathic dilated cardiomyopathy
Clinical trials : 11 / Drugs : 23 - (DrugBank : 12) / Drug target genes : 9 - Drug target pathways : 35
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01917149 (ClinicalTrials.gov) | March 2005 | 30/7/2013 | Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy | Efficacy and Safety Study of Supramaximal Titrated Inhibition of RAAS in Idiopathic Dilated Cardiomyopathy | Dilated Cardiomyopathy | Drug: Benazepril;Drug: Valsartan;Drug: Metoprolol | Xijing Hospital | NULL | Completed | 18 Years | 70 Years | Both | 480 | Phase 4 | China |
218. Alport syndrome
Clinical trials : 30 / Drugs : 36 - (DrugBank : 15) / Drug target genes : 8 - Drug target pathways : 46
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04937907 (ClinicalTrials.gov) | September 8, 2021 | 17/6/2021 | Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS) | Efficacy and Safety of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS) | Alport Syndrome, X-Linked | Drug: Hydroxychloroquine Sulfate 100 milligram (mg) Tab;Drug: Benazepril hydrochloride 10 milligram (mg) Tab | Shanghai Children's Hospital | NULL | Recruiting | 3 Years | 18 Years | All | 50 | Phase 2 | China |
| 2 | ChiCTR2000036799 | 2020-10-01 | 2020-08-25 | Construction and clinical transformation of integrated platform for accurate diagnosis and treatment of Alport syndrome | Construction and clinical transformation of integrated platform for accurate diagnosis and treatment of Alport syndrome | Alport Syndrome | experimental group:Hydroxychloroquine + Benazepril Hydrochloridec;control group:placebo + benazepril hydrochloride; | Shanghai Children's Hospital | NULL | Pending | 0 | 18 | Both | experimental group:25;control group:25; | N/A | China |
| 3 | NCT00309257 (ClinicalTrials.gov) | January 2004 | 30/3/2006 | Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome | Effects of an Intensified Treatment With ACE-inhibitors, Angiotensin II Receptor Antagonists and Statins in Alport Syndrome | Alport Syndrome | Drug: ACE I, ATA II and Statins;Drug: Benazepril, Valsartan and Fluvastatin | Mario Negri Institute for Pharmacological Research | NULL | Completed | 15 Years | 70 Years | Both | 9 | Phase 2 | Italy |
224. Purpura nephritis
Clinical trials : 16 / Drugs : 43 - (DrugBank : 21) / Drug target genes : 15 - Drug target pathways : 58
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03591471 (ClinicalTrials.gov) | September 2014 | 9/12/2014 | Study on Children Henoch-Schönlein Purpura Nephritis With TCM Multistep Treatment | Demonstrated Study on Children Henoch-Schönlein Purpura Nephritis With Multistep Treatment of Traditional Chinese Medicine Combined Disease and Syndrome Differentiation | Henoch-Schönlein Purpura Nephritis | Drug: Glycosides Of Tripterygium Wilfordii Hook(GTW);Drug: Sulfotanshinone Sodium Injection;Drug: Chinese herbs based on syndrome differentiation;Drug: Prednisone Acetate Tablets;Drug: Benazepril Hydrochloride Tablets;Drug: Low Molecular Weight Heparin Calcium Injection;Drug: Dipyridamole Tab 25 MG;Drug: Chinese medicine placebo | Henan University of Traditional Chinese Medicine | Peking University First Hospital;Children's Hospital of Fudan University;Shanghai Children's Hospital;Chengdu University of Traditional Chinese Medicine;Affiliated Hospital of Yunnan University of Traditional Chinese Medicine | Unknown status | 2 Years | 18 Years | All | 500 | Phase 1/Phase 2 | China |